Atopic dermatitis: Latest News, Top Stories & Analysis

WILMINGTON, DE — Incyte (Nasdaq: INCY) has expanded its Moments of Clarity program, adding six new personal stories that illuminate the lived experiences of people managing chronic immune-mediated skin conditions, …

Regional

FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis

September 28, 2025September 27, 2025 - by Timothy Alexander

WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate …

Research

Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment

June 2, 2025June 2, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …

Research

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis

September 19, 2024September 17, 2024 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …